Investor Sofinnova Venture Partners X, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sofinnova Venture Partners X, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2024-03-26 13D/A VERA / Vera Therapeutics, Inc. 3,648,296 2,813,837
2024-02-20 13D/A VERA / Vera Therapeutics, Inc. 3,477,081 3,648,296
2024-02-20 13D/A INZY / Inozyme Pharma, Inc. 2,028,308 4,280,308
2024-02-20 13D/A AVTE / Aerovate Therapeutics, Inc. 3,783,632 3,807,315
2023-06-21 13D/A KRTX / Karuna Therapeutics, Inc. 1,826,624 1,439,649
2023-03-01 13D/A CINC / CinCor Pharma Inc 6,109,360 0
2023-02-14 13D/A VERA / Vera Therapeutics, Inc. 3,191,367 3,477,081
2023-02-06 13D/A VERA / Vera Therapeutics, Inc. 2,914,776 3,191,367
2023-02-06 13D/A KRTX / Karuna Therapeutics, Inc. 1,729,352 1,826,624
2023-02-06 13D/A AVTE / Aerovate Therapeutics, Inc. 3,760,074 3,783,632
2022-08-22 13D/A CINC / CinCor Pharma Inc 5,573,949 6,109,360
2022-02-15 13D/A YMAB / Y-mAbs Therapeutics, Inc. 2,111,389 2,271,611
2022-01-21 13D CINC / CinCor Pharma Inc 5,573,949
2021-07-13 13D AVTE / Aerovate Therapeutics, Inc. 3,760,074
2021-05-24 13D VERA / Vera Therapeutics, Inc. 2,914,776
2021-03-04 13D INZY / Inozyme Pharma, Inc. 2,028,308
2019-07-03 13D KRTX / Karuna Therapeutics, Inc. 1,729,352
2018-10-02 13D YMAB / Y-mAbs Therapeutics, Inc. 2,111,389